Overview

Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors

Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
immunotherapy，gastric cancer，rectal cancer，biomark
Phase:
Phase 2
Details
Lead Sponsor:
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Treatments:
Trastuzumab